Literature DB >> 22124844

Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Alessia Locatelli1, Kristopher A Lofgren, Andrea R Daniel, Nancy E Castro, Carol A Lange.   

Abstract

Signal transduction pathways downstream of receptor tyrosine kinases (RTKs) are often deregulated during oncogenesis, tumor progression, and metastasis. In particular, the peptide growth factor hormone, hepatocyte growth factor (HGF), and its specific receptor, Met tyrosine kinase, regulate cancer cell migration, thereby conferring an aggressive phenotype (Nakamura et al., J Clin Invest 106(12):1511-1519, 2000; Huh et al., Proc Natl Acad Sci U S A 101:4477-4482, 2004). Additionally, overexpression of Met is associated with enhanced invasiveness of breast cancer cells (Edakuni et al., Pathol Int 51(3):172-178, 2001; Jin et al., Cancer 79(4):749-760, 1997; Tuck et al., Am J Pathol 148(1):225-232, 1996). Here, we review the regulation of recently identified novel downstream mediators of HGF/Met signaling, Breast tumor kinase (Brk/PTK6), and Src-associated substrate during mitosis of 68 kDa (Sam68), and discuss their relevance to mechanisms of breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22124844      PMCID: PMC3971994          DOI: 10.1007/s12672-011-0097-z

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  150 in total

1.  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Authors:  Carrie R Graveel; Jack D DeGroot; Yanli Su; Julie Koeman; Karl Dykema; Samuel Leung; Jacqueline Snider; Sherri R Davies; Pamela J Swiatek; Sandra Cottingham; Mark A Watson; Matthew J Ellis; Robert E Sigler; Kyle A Furge; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-30       Impact factor: 11.205

2.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells.

Authors:  M Ivan; J A Bond; M Prat; P M Comoglio; D Wynford-Thomas
Journal:  Oncogene       Date:  1997-05-22       Impact factor: 9.867

Review 3.  Brk/PTK6 signaling in normal and cancer cell models.

Authors:  Julie H Ostrander; Andrea R Daniel; Carol A Lange
Journal:  Curr Opin Pharmacol       Date:  2010-09-09       Impact factor: 5.547

4.  Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Authors:  Kelly L Mueller; Lauren A Hunter; Stephen P Ethier; Julie L Boerner
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 5.  Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases.

Authors:  Michael S Serfas; Angela L Tyner
Journal:  Oncol Res       Date:  2003       Impact factor: 5.574

6.  Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA.

Authors:  W M Mars; R Zarnegar; G K Michalopoulos
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

7.  Role of the Brk SH3 domain in substrate recognition.

Authors:  Haoqun Qiu; W Todd Miller
Journal:  Oncogene       Date:  2004-03-18       Impact factor: 9.867

8.  Diverse and potent activities of HGF/SF in skin wound repair.

Authors:  Damon Bevan; Ermanno Gherardi; Tai-Ping Fan; Dylan Edwards; Richard Warn
Journal:  J Pathol       Date:  2004-07       Impact factor: 7.996

9.  Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator.

Authors:  K Miyazawa; T Shimomura; N Kitamura
Journal:  J Biol Chem       Date:  1996-02-16       Impact factor: 5.157

10.  HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion.

Authors:  Hanane Khoury; Monica A Naujokas; Dongmei Zuo; Veena Sangwan; Melanie M Frigault; Stephanie Petkiewicz; David L Dankort; William J Muller; Morag Park
Journal:  Mol Biol Cell       Date:  2004-11-17       Impact factor: 4.138

View more
  28 in total

1.  Knockdown of c-MET induced apoptosis in ABCB1-overexpressed multidrug-resistance cancer cell lines.

Authors:  T-H Hung; Y-H Li; C-P Tseng; Y-W Lan; S-C Hsu; Y-H Chen; T-T Huang; H-C Lai; C-M Chen; K-B Choo; K-Y Chong
Journal:  Cancer Gene Ther       Date:  2015-04-24       Impact factor: 5.987

2.  Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.

Authors:  Tiffany Tsui; W Todd Miller
Journal:  Biochemistry       Date:  2015-05-13       Impact factor: 3.162

3.  PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer.

Authors:  Yu Zheng; Zebin Wang; Wenjun Bie; Patrick M Brauer; Bethany E Perez White; Jing Li; Veronique Nogueira; Pradip Raychaudhuri; Nissim Hay; Debra A Tonetti; Virgilia Macias; André Kajdacsy-Balla; Angela L Tyner
Journal:  Cancer Res       Date:  2013-07-15       Impact factor: 12.701

4.  Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.

Authors:  You-Fang Chen; Gang Ma; Xun Cao; Zhi-Liang Huang; Mu-Sheng Zeng; Zhe-Sheng Wen
Journal:  Med Oncol       Date:  2014-11-07       Impact factor: 3.064

Review 5.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

6.  The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.

Authors:  Mohamed M Mohyeldin; Mohamed R Akl; Abu Bakar Siddique; Hossam M Hassan; Khalid A El Sayed
Journal:  Biochem Pharmacol       Date:  2016-12-08       Impact factor: 5.858

7.  Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage.

Authors:  Jessica J Gierut; Priya S Mathur; Wenjun Bie; Jin Han; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2012-09-18       Impact factor: 6.261

Review 8.  Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications.

Authors:  Aixiu Qiao; Feng Gu; Xiaojing Guo; Xinmin Zhang; Li Fu
Journal:  Front Med       Date:  2016-01-20       Impact factor: 4.592

Review 9.  Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer.

Authors:  Yu Zheng; Angela L Tyner
Journal:  Eur J Clin Invest       Date:  2013-02-10       Impact factor: 4.686

10.  Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells.

Authors:  Gaofeng Fan; Guang Lin; Robert Lucito; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.